PCSK9 and cardiovascular disorder: More intensive lipid-lowering therefore might be justified in patients with coexisting cardiovascular disease, although economic evaluation of PCSK9 inhibitors in addition to statin therapy in similar patient populations suggests that treatment might still exceed the generally accepted cost-effectiveness threshold,32 and there is probably still potential for more intensive treatment with statins and other lipid-lowering drugs.